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INTRODUCTION
Since the first report of the GFJ effect on the oral bioavailability of felodipine (Bailey et al., 1989 (Bailey et al., , 1991 , many studies for identifying the active components responsible for the GFJ effects have been reported (Bailey et al., 1993 , Edwards et al., 1996 Fukuda et al. 1997; Schmiedlin-Ren et al., 1997 , He et al., 1998 Guo et al., 2000; Ho et al., 2001 ).
GFJ composition varies from variety to variety and from lot to lot and also depends on the preparation method (De Castro et al., 2006) . In all cases, the majority of the constituents are flavonoids (Ho et al., 2000) . Naringin, a predominant constituent in GFJ, is present in concentrations up to 2000 µM (Ross et al., 2000) . Even relatively low abundant flavonoids such as quercetin exist in 20µM range. Bergamottin and 6',7'-dihydroxybergamottin (6',7'-DHB) being the most abundant furanocoumarin derivatives, another well studied GFJ constituent , present in concentrations up to 40 µM (Edwards et al., 1996) . Though many bioflavonoids inhibited CYP3A in vitro (Ho et al., 2001) , in vivo, naringin by itself at concentrations found in GFJ was not capable of producing a clinical drug interaction such as seen with grapefruit juice (Bailey et al., 1998) . Several furanocoumarins in grapefruit juice are effective in vitro CYP3A inhibitors and are currently suggested to be clinical active constituents (Schmiedlin-Ren et al., 1997 , He et al., 1998 .
Our previous study demonstrated that GFJ inhibits esterase activity and mediates pharmacokinetic interaction with ester prodrugs lovastatin and enalapril. It is important to identify the active components responsible for this new esterase-mediated GFJ effects in vivo. Several classical esterase inhibitors are known including diethyl p-nitrophenyl This article has not been copyedited and formatted. The final version may differ from this version. (Walker et al., 1983 ) and bis-p-nitrophenylphosphate (BNPP) (Gratzl et al., 1975) . However, the extreme toxicity of these compounds precludes their clinical use.
Recently, a series of synthesized benzene sulfonamides and the aromatic dione family were identified as selective inhibitors of CEs (Wadkins et al., 2004 and . Likewise, flavoring ester mixtures in strawberry juice were also reported to interact with prodrug tenofovir leading to enhanced permeability across Caco-2 (Van Gelder et al., 2002) . Our recent report (Li. et al., manuscript submitted) demonstrated that GFJ decreased lovastatin and enalapril hydrolysis in the gut, and thereby markedly increased metabolic stability and permeability of esters, leading to the enhancement of exposure to lovastatin acid and enalaprilat in rats. In the current report, the esterase inhibition potential of ten grapefruit juice components towards PNPA hydrolysis as well as the effect of two selected components on the esterase mediated changes in the permeability in in vitro systems, and in in vivo rat exposure to active acids of enalapril and lovastatin upon coadministration are described.
This article has not been copyedited and formatted. The final version may differ from this version. Inhibition of esterase activity in purified porcine esterase and human liver microsomes. Purified porcine liver esterase (5 munit/mL) or human liver microsomes (0.1 mg/mL) in 0.1 M potassium phosphate buffer pH 7.4 was incubated at 37 0 C with PNPA (667 µM) and one of the ten GFJ components of ten different concentrations bergamottin (0~100 µM), bergapten (0~ 100 µM), 6',7'-DHB (0 ~ 100 µM), kaempferol Permeability in Caco-2 membrane. Caco-2 cell cultures were prepared as described previously (Xia et al., 2005) . Single directional transport studies were performed at 37°C 
Data analysis
Percent inhibition of PNPA hydrolysis for each inhibitor was calculated as the ratio of OD at each concentration of inhibitor with respect to that in the absence of the inhibitor, and the percentages were plotted against the concentrations of each tested inhibitor using Prism software (GraphPad, San Diego, CA). The sigmoidal dose-response (variable slope) model was used to determine the concentration that gave 50% inhibition (IC 50 ).
The IC 50 was calculated using the equation
where X is the logarithm of concentration, and Y is the percent activity.
PK parameters were calculated by noncompartmental analysis WinNonlin software Version 5.1 (Pharsight, Mountain view, CA). Statistical analysis was using student t-test.
Apparent permeability (P app , cm/sec x 10 -6 ) was calculated using the equation 
Results
Effect of GFJ components on purified porcine esterase and human liver microsomal hydrolase activity. Inhibitory activity of GFJ components towards esterase activity varied widely. Bergamottin, 6',7'-DHB and bergapten (each at 100 µM), hesperidin at 200 µM, and naringin at 1000 µM did not show appreciable inhibition of the hydrolysis of PNPA by porcine liver esterase. However, morin, galangin, kaempferol, quercetin, and naringenin showed inhibitory effects. Estimates of IC 50 were 1.8 µM for morin, 2.8 µM for galangin, 5.1 µM for kaempferol, 5.9 µM for quercetin, and 110 µM for naringenin (Table 1) . Likewise, in human liver microsomes bergamottin, 6',7'-DHB, bergapten, naringin and hesperidin did not appreciably inhibit the hydrolysis of PNPA.
Estimates of IC 50 for human liver microsomes were 80 µM for morin, 81 µM for galangin, 62 µM for kaempferol, 43 µM for quercetin, and 30 µM for naringenin.
Effect of kaempferol and naringenin on A-to-B permeability in Caco-2 cells. The permeability of lovastatin was not altered by GF120918 alone (-0.5%), and was increased by 65%, 64%, and 66% by kaempferol (250 µM), naringenin (250 µM), and the mixture of kaempferol (250 µM) and GF120918 (2 µM; Figure 1A ). In Caco-2 cells, at 1 hr, the intracellularly trapped lovastatin was not significantly altered, with the respective values of 117%, 95.8%, 105%, and 116% of the control (1316 pmol), whereas the trapped amount of lovastatin acid was unaffected by GF120918 alone (120%) and decreased to 54.5%, 28.6%, and 51.6% by kaempferol, naringenin, and mixture of kaempferol and GF120918 relative to the control (161 pmol). The overall ratios of lovastatin acid to lovastatin in Caco-2 cells were decreased and are shown in Figure 1B . Figure 2A ). The corresponding intracellularly trapped enalapril in Caco-2 cells at 1 hr was increased by 67.3%, 69.1%, 26.2%, and decreased by 11% relative to the control (9.9 pmol); and enalaprilat was decreased to 54.5, 36.8, 57.8, and 39.7% relative to the control (41 pmol). The overall ratios of enalaprilat to enalapril were decreased and are shown in Figure 2B . The amount of lovastatin acid and enalaprilat on the donor side, at the end of the incubation, was very low and was not affected by kaempferol and naringenin.
Effect of kaempferol and naringenin on enalapril and lovastatin hydrolysis in rat liver microsomes or S9 fractions. The percent of lovastatin hydrolyzed in rat liver S9
(8.8 pmol/min/mg) was reduced to 55%, 72% and 54%, and 24% of the control by kaempferol, naringenin, BNPP, and PMSF, respectively ( Figure 3A ). Enalapril hydrolysis in rat liver microsomes (62.8 pmol/min/mg) was reduced to 29%, 66%, 19%, and 1% of the control by kaempferol, naringenin, BNPP, and PMSF, respectively ( Figure   3B ).
Effect of kaempferol and naringenin on oral PK of lovastatin acid and enalaprilat in rats.
The plasma concentration-time profiles of lovastatin acid and enalaprilat in rats following oral co-administration of lovastatin and enalapril (10 mg/kg) with water, kaempferol (2 and 10 mg/kg), and naringenin (2 and 10 mg/kg) are shown in Figure 4 and 5. The PK data are shown in Table 2 .
Effect of kaempferol on the portal plasma PK of lovastatin. The portal vein plasma concentration-time profiles of lovastatin, lovastatin acid, and the major oxidative product, 6'β-hydroxylovastatin, following oral co-administration of lovastatin (10 mg/kg) to rats This article has not been copyedited and formatted. The final version may differ from this version. with water or kaempferol (10 mg/kg) are shown in Figure 6 . The 6'β-hydroxylovastatin was identified by LC/MS/MS spectral comparison with the published data (Halpin et al., 1993) , and quantitated in plasma using lovastatin standard curves. The portal plasma PK parameters are shown in Table 3 . The AUC ratio of 6'β-hydroxylovastatin and lovastatin was 0.064 and 0.078 to rats upon coadministration of lovastatin with water and kaempferol, respectively.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussions
Inhibition of esterase activity in purified porcine esterase and human liver microsomes. The ten grapefruit components investigated in this study belong to two major and widely known classes, flavonoids (aglycones and glycosides) and furanocoumarins. In the earlier years, grapefruit flavonoids were extensively studied for their CYP3A inhibition potential for understanding the GFJ effect on oral bioavailability of CYP3A substrates. Though these flavonoids in vitro inhibited CYP3A4 but they did not reproduce the grapefruit juice effect when administered orally (Rashid et al. 1993 , Bailey et al. 1993 . Currently, it is believed that grapefruit furanocoumarins, bergamottin and 6',7'-DHB in GFJ are responsible for the GFJ interaction by competitive and mechanism-based inhibition of CYP3A in the small intestine. These two potent CYP3A
inhibitors, in the current study, were found to be devoid of esterase inhibitory activity in purified porcine esterase and human liver microsomes, at 100 µM, a concentration higher than that was found in GFJ. Some of the flavonoids on the other hand were found to have esterase inhibitory activity. The effect of flavonoids in aglycones form on carboxylesterases is distinguishable different from flavonoids in glycoside form.
Naringin and hesperidin, the two glycosidic flavonoids, did not inhibit PNPA hydrolysis at concentrations found in GFJ. However, the five flavonoids morin, galangin, necessarily reflect species differences. Nevertheless, these data show that there is potential of esterase inhibition by these flavonoids in vivo in humans. The combined effects of flavonoids could contribute significantly to the GFJ effects on PK of ester prodrugs. The effects of kaempferol and naringenin, two of the major and potent esterase inhibitory flavonoids in GFJ, on enalapril and lovastatin's permeability in Caco-2 model, hydrolysis in rat liver system, and PK in rats were examined. Kaempferol was reported to inhibit CYP3A and Pgp in vitro (Jignesh et al., 2004) . Caco-2 cells used in our study were determined to show Pgp and esterase activities, but only a minor CYP3A activity (data not shown). Thus, in this Caco-2 model the effect of kaempferol on lovastatin could mainly be due to Pgp and/or esterase. Kaempferol and naringenin led to enhancement of A B permeability of lovastatin and enalapril ( Figures 1A and 2A ).
GF120918, a Pgp and BCRP inhibitor (Xia et al., 2005) , failed to significantly alter lovastatin permeability suggesting that the contribution of Pgp to the permeability of lovastatin was negligible. Thus, it is mainly the esterase inhibition attribute of kaempferol and naringenin that led to the higher permeability of lovastatin and enalapril.
As expected, in these experiments the intracellularly trapped lovastatin acid and enalaprilat were reduced by kaempferol and naringenin, as indicated by decreases in the ratios of lovastatin acid to lovastatin to 59%, 27% and 45% by kaempferol, naringenin and a mixture of kaempferol and GF120918 ( Figure 1B) , and enalaprilat to enalapril to 27%, 19%, 44% and 38% by kaempferol (50 and 250 µM) and naringenin (50 and 250
µM), respectively (Figures 2B).
This article has not been copyedited and formatted. The final version may differ from this version. Esterase inhibition in vitro and in vivo in rats. Hydrolysis of enalapril in rat liver microsomes or hydrolysis of lovastatin in rat liver S9 fraction was inhibited by both kaempferol and naringenin, two of the major flavonoids in GFJ. Kaempferol appeared to be more potent esterase inhibitor than naringenin in rat liver system. In vivo, the AUC of lovastatin acid was increased by 171%, 246%, 159%, and 288% in rats following oral administration of lovastatin with kaempferol (2 and 10 mg/kg) and naringenin (2 and 10 mg/kg), respectively, compared to dosing with water (Table 2 ). Practically no unchanged lovastatin was detected in plasma, because of its rapid hydrolysis by plasma esterases.
BNPP, a known esterase inhibitor (Walker et al., 1983) , produced an effect similar to kaempferol and naringenin (Li et al., manuscript submitted). The positive BNPP effect suggested that the esterase plays a significant role in modulating the oral exposure to lovastatin. Thus, the large increase in AUC observed with kaempferol and naringenin was a combination of their effects due to CYP3A and esterase inhibition. In order to differentiate the modes of kaempferol and naringenin effects via CYP3A inhibition, esterase inhibition, and/or combination of both, portal vein-cannulated rats were dosed with water or with kaempferol (10 mg/kg). The portal plasma exposure of lovastatin acid, lovastatin, and 6'β-hydroxylovastatin with kaempferol showed 113%, 154%, and 208% higher AUC than dosing with water. Once absorbed, lovastatin is rapidly converted to lovastatin acid in rat plasma with a half-life shorter than five minutes.
Lovastatin is known to be metabolized by CYP3A to 6'β-hydroxylovastatin as one of the major oxidized products (Halpin et al., 1993) . The possible effect of kaempferol on lovastatin exposure by inhibiting intestinal CYP3A was examined by comparing AUC ratio of oxidized metabolite 6'β-hydroxylovastatin to lovastatin. The 6'β-This article has not been copyedited and formatted. The final version may differ from this version. (Halpin et al., 1993) , and quantitated in plasma using lovastatin standard curves.
The AUC ratio of 6'β-hydroxylovastatin to lovastatin stayed low at 0.064 and 0.078 for coadministration with water and kaempferol, respectively (Table 3) indicating that kaempferol did not markedly inhibit CYP3A activity in rats. This finding is consistent with the literature that kaempferol and naringenin are weak CYP3A inhibitor with IC 50 value greater than 100 µM (Ho et al., 2001) . In general, the absorption of GFJ components is considered to be poor, and their action is postulated to be mainly in the small intestine (Schmiedlin-Ren et al.,1997; He et al., 1998) .
The exposure to enalaprilat was also increased by 18%, 38%, 60%, and 109% in rats following oral administration of enalapril with naringenin (2 and 10 mg/kg) and kaempferol (2 and 10 mg/kg), respectively, compared to dosing with water ( Figure 5 , Table 2 ). Enalapril is only metabolized by carboxylesterase (hCE1), and is not a CYP3A substrate, thus the esterase inhibition by kaempferol and naringenin led to oral exposure increase of enalaprilat in rats. This is consistent with the increased exposure of enalapril when coadministered with the esterase inhibitor BNPP (Li et al., manuscript submitted), as well as with the in vitro data.
Overall, the study identified the flavonoids as active components in grapefruit juice partly responsible for esterase inhibitory activity in vitro in rat liver, and human liver and Caco- 
